Tag
Intravitreal pegcetacoplan significantly slowed geographic atrophy progression by 41% over two years, maintaining efficacy in clinical practice for AMD patients, with stable visual acuity decline and manageable safety.
Vision-related quality of life in geographic atrophy secondary to AMD is most strongly linked to lesion extent within a 2.5-mm central retinal zone, emphasizing targeted structural assessment for functional impact.
This study identifies three candidate geographic atrophy phenotypes in age-related macular degeneration, revealing distinct growth rates and severity, with implications for prognosis and clinical trials.
Avacincaptad pegol significantly reduces progression of ellipsoid zone degradation and geographic atrophy lesion growth, highlighting its potential to preserve photoreceptor integrity in AMD patients.
This review synthesizes evidence on improving geographic atrophy trial efficiency through innovative run-in phases, single-arm designs, and superior functional biomarkers like microperimetry to reduce required sample sizes.
A post hoc analysis of AREDS2 reveals that geographic atrophy enlargement rates between fellow eyes show only modest correlations, challenging the common assumption that bilateral GA progresses similarly. The findings have important implica
Researchers have developed and validated GAWAIN, a novel structural measure for geographic atrophy that weights macular regions by their functional importance. This index correlates significantly better with visual acuity than traditional a
A groundbreaking study published in NEJM demonstrates that the PRIMA subretinal photovoltaic system significantly improves visual acuity in patients with geographic atrophy, marking a major milestone in restorative ophthalmology.
A UK study reveals most patients with geographic atrophy are open to intravitreal complement inhibitor injections if these treatments offer vision improvement, highlighting the vital role of functional benefits in therapy acceptance.
